The Global Health Body Issues Concern Over Critical Scarcity of Weight-Loss Injections

Under 10% of individuals that would benefit from obesity jabs including Wegovy have access to them, states the global health agency as it publishes its inaugural recommendations on the medications.

Given in excess of 1,000,000,000 people worldwide now obese, it is calling for increased and just availability to these injectable treatments.

According to forecasts, over two billion are projected to be obese by 2030 unless action is taken.

"Our latest guidance affirms that obesity is a lifelong illness that can be addressed with thorough and lifelong treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.

Significant expense, insufficient output, and distribution challenges are major hurdles to widespread access to the jabs that can help people shift considerable weight, explains the body.

GLP-1 Therapy Scarcity

Even in the current most favorable outlook, the manufacturing of these medications could only cover about 100 million people – under 10% of eligible patients, per the health organization.

The guideline urges nations and manufacturers to increase access, by strategies including patent sharing.

A patent on a key compound – the main ingredient of a leading brand – is due to expire in a number of nations in 2026.

The Way Weight-Loss Jabs Operate

The injections mimick a biological compound to slow digestion, curb appetite and increase satiety so people eat less.

Individuals usually start to lose weight in the initial weeks of starting on the regular doses.

Research points to users may regain a significant portion a year later of discontinuing the treatment, as their typical food cravings return.

Being above a healthy weight increases your chance for developing health problems, such as type 2 diabetes, cardiovascular issues, stroke, and certain cancers.

Excess weight affects people in all nations and was linked to 3.7 million deaths worldwide in 2024, according to the health agency.